Tabelecleucel is a type of therapy that uses special immune cells called T cells. These T cells are designed to target and destroy cells infected with the Epstein-Barr virus (EBV). This therapy is being studied to see if it can help people with diseases related to EBV by improving their condition.

EBV+ associated post-transplant lymphoproliferative disorder involving the central nervous system (EBV+ CNS PTLD) – This disease occurs when abnormal growth of lymphoid cells happens in the central nervous system after a transplant, often due to Epstein-Barr virus (EBV) infection. It typically develops in individuals with weakened immune systems, such as those who have undergone organ transplants. The disease can lead to neurological symptoms as it affects the brain and spinal cord. Over time, it may cause cognitive and motor function impairments. The progression can vary, with some cases remaining stable while others may worsen.

EBV+ primary immunodeficiency lymphoproliferative disease (LPD) – This condition arises in individuals with primary immunodeficiency, where the immune system is inherently weak, leading to uncontrolled growth of lymphoid cells due to EBV infection. It can manifest with symptoms like swollen lymph nodes, fever, and fatigue. The disease may progress with the development of tumors or other complications. The severity and progression can differ based on the underlying immune deficiency and the body’s response to the virus.

EBV+ associated lymphoproliferative disease in the setting of acquired (non-congenital) immunodeficiency (EBV+ AID LPD) – This disease occurs in individuals who have acquired immunodeficiency, such as from HIV infection or immunosuppressive therapy, leading to abnormal lymphoid cell growth due to EBV. Symptoms can include fever, weight loss, and enlarged lymph nodes. The disease may progress with the potential for organ involvement and further immune system compromise. The course of the disease can vary depending on the level of immunosuppression and viral activity.

EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors – These are rare tumors associated with EBV infection, affecting smooth muscle tissues such as those in the gastrointestinal tract or blood vessels. They can present as masses or lumps and may cause pain or obstruction depending on their location. The progression of these tumors can vary, with some growing slowly while others may be more aggressive. The disease can lead to complications based on the size and location of the tumors.

EBV+ post-transplant lymphoproliferative disorder where standard first-line therapy is inappropriate, including CD20-negative disease – This condition occurs when lymphoid cells grow uncontrollably after a transplant, and standard treatments like rituximab or chemotherapy are not suitable, often due to the absence of CD20 markers. It can present with symptoms such as fever, weight loss, and swollen lymph nodes. The disease may progress with potential organ involvement and further immune system compromise. The progression can vary, with some cases remaining stable while others may worsen.